Abstract: The present invention provides storage stable, shaped particles of allotropic organic compounds. The particles of the present invention can be shaped according to the desired application. Preferred shapes of such particles are microspheres, particularly those having diameters of about 1 to about 1,000 microns. The stable shaped particles of the present invention are particularly well-suited to the fabrication of pharmaceutical formulations, particularly where sustained release and uniform bioavailability are desired. The storage stable particles are formed by a solid state crystallization of allotropic organic compounds. The solid state crystallization process of the present invention affords a means for achieving a storage stable crystalline form of said allotropic compound without loss or deterioration of the original particle dimensions.
Type:
Grant
Filed:
February 26, 2003
Date of Patent:
May 18, 2004
Inventors:
John-Claude Savoir, Juan Angeles, Aurelio De Gyves, Abraham Gomez
Abstract: The present invention provides a thermodynamically stable modification of (±)1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole and pharmacologically acceptable salts or optically active forms thereof as well as processes for their preparation and pharmaceutical compositions containing one or more of them.
Abstract: A composition and method for suppressing pain and irritation of tissue uses an anti-irritant in an effective amount to suppress pain and irritation temporarily when applied topically to the skin, mucosa, or the eye. The anti-irritant is a natural or non-nutritive sweetener. The composition can contain an edible acid such as citric acid and ascorbic acid from fresh lemon juice to provide a pH of about 2.0 to 4.0 and an anti-irritant, such as sodium saccharine. The composition can be used to treat cuts, scratches and abrasions on the skin and for applying a pharmaceutical agent to the skin, mucosa or eye without irritation. The acidic composition can further be used to remove or loosen calculus deposits from the teeth without burning or irritation of the gums.
Abstract: The present invention relates to an oral modified release pharmaceutical composition for the administration of a therapeutically and/or prophylactically effective amount of an active substance (a drug substance), to obtain a relatively fast or quick onset of the therapeutic and/or prophylactic effect. The drug substances contained in a modified release pharmaceutical composition according to the invention are suitably a drug substance which has a pKa value below about 5, such as in a range of from about 4 to about 5.
Type:
Grant
Filed:
July 10, 2001
Date of Patent:
March 30, 2004
Assignee:
Nycomed Danmark A/S
Inventors:
Poul Bertelsen, Niels Gjørløv Hansen, Hermann Ruckendorfer, Shigeru Itai
Abstract: A low viscosity filler boron nitride agglomerate particles having a generally spherical shape bound together by an organic binder and to a process for producing a BN powder composition of spherically shaped boron nitride agglomerated particles having a treated surface layer which controls its viscosity.
Type:
Grant
Filed:
January 3, 2001
Date of Patent:
March 30, 2004
Assignee:
General Electric Company
Inventors:
David Lodyga, Joseph W. Tereshko, Ajit Sane, Thomas Fox
Abstract: Contraceptive methods, systems, and devices generally improve the ease, speed, and reliability with which a contraceptive device can be deployed transcervically into an ostium of a fallopian tube. The contraceptive device may remain in a small profile configuration while a sheath is withdrawn proximally, and is thereafter expanded to a large profile configuration engaging the surrounding tissues, by manipulating one or more actuators of a proximal handle with a single hand. This leaves the other hand free to manipulate a hysteroscope, minimizing the number of health care professional required to deploy the contraceptive device.
Type:
Grant
Filed:
August 22, 2000
Date of Patent:
March 23, 2004
Assignee:
Conceptus, Inc.
Inventors:
Christian Lowe, Don Gurskis, Ashish Khera, Monica Barnhart, Steven Bacich, Betsy Swann, Roberto Silva-Torres
Abstract: Disclosed are an enteric coated formulation of a benzimidazole derivative comprising a core and a film of an enteric coating agent on the surface thereof, the core containing a complex of the benzimidazole derivative and an ion-exchange resin, and the enteric coating agent having the degree of substitution by an acidic group of less than 30%, and a method for preparation thereof.
Abstract: Compositions for implantation into the human and animal body as bone replacement contain inter alia calcium and phosphorus and consist in particular of mixtures of powders and admixing liquids. They are suitable for preparing calcium phosphate cement pastes which cure at room and/or body temperature. The reaction systems contain a powdery base mixture comprising CaKPO4, Ca2NaK(PO4)2 and Ca(H2PO4)2.H2O.
Abstract: Described is a composition of matter comprising a powdered, water-soluble, water-dispersible or water-swellable polymer, a compatible fragrance, either as a blend of fragrance with polymer or separately mixed, and one or more surfactants. The polymer may be extruded polyvinyl alcohol or partially hydrolyzed polyvinyl acetate. Also described is a toilet element moulded from the composition of matter, which may be either a toilet rim block for use in a toilet bowl, or a free-standing block for use in a toilet cistern, and processes for comparing the composition of matter and toilet element.
Abstract: The present invention is directed a pharmaceutical composition which can be administered orally, allowing for the controlled release of at least one active substance. The composition includes at least one active substance, between 5 and 60% by weight, relative to the total weight of the composition, of at least one excipient, selected from inert matrices, hydrophilic matrices, lipid matrices, mixtures of inert matrices and of lipid matrices, and mixtures of hydrophilic matrices and of inert matrices, with the exception of mixtures including a polyacrylic acid and at least one hydrophilic matrix of the cellulose type; and between 5 and 50% by weight, relative to the total weight of the composition, of at least one alkalinizing agent soluble in an aqueous phase under physiological pH conditions, selected from alkali or alkaline-earth metal hydroxides, carbonates, bicarbonates, phosphates, sodium borate and basic salts of organic acids.
Type:
Grant
Filed:
September 29, 1999
Date of Patent:
March 2, 2004
Assignee:
UCB, S.A.
Inventors:
Domenico Fanara, Monique Berwaer, Anne Bouquelle, Michel Deleers
Abstract: The invention concerns a pharmaceutical composition with prolonged release, for oral administration of a single daily dose of 60 to 140 mg of Milnacipran, having a multi-particulate form containing a plurality of microgranules each comprising an active microsphere containing a saccharose and/or starch nucleus of a size between 200 and 2000 &mgr;m and containing 150 to 1000 &mgr;m of Milnacipran and a binding agent, each microgranule being coated with a film having a base of at least one polymer insoluble in water but permeable to physiological liquids, of a thickness between 20 and 100 &mgr;m, the said pharmaceutical composition enabling an in vitro release corresponding to the following pattern: between 10 and 55% of the dose released in 2 hours, between 40 and 75% of the dose released in 4 hours, between 70 and 90% of the dose released in 8 hours, between 80 and 100% of the dose released in 12 hours.
Type:
Grant
Filed:
February 26, 1999
Date of Patent:
March 2, 2004
Assignee:
Pierre Fabre Medicament
Inventors:
Bruno Paillard, Eric Goutay, Jean-Louis Avan, Joël Bougaret
Abstract: An orally administered preparation with controlled lease of an opioid analgesic in the form of crystals having particle size of 10 &mgr;m to 3 mm, preferably of 50 &mgr;m to 1 mm, which have at least one controlled release coating.
Type:
Grant
Filed:
January 18, 2000
Date of Patent:
February 3, 2004
Assignee:
Gruenenthal GmbH
Inventors:
Johannes Bartholomaeus, Juergen Betzing
Abstract: Individually dosed active substance-containing and, in particular, aromatic-containing, film-shaped administration form, rapidly disintegrating upon contact with a liquid, wherein the aromatic is present as an internal, liposoluble phase in the form of liquid droplets distributed within an outer, solid but water-soluble phase, is characterized in that the said outer phase contains:
at least 40% (w/w) polyvinyl alcohol
0 to 30% (w/w) of a surface-active substance, and that the constituent amount of the inner phase, relative to the outer phase, is between 0.1 and 30% (w/w), in each case relative to the water-free portions.
Abstract: A dry extract is reduced in volume by compacting to produce a solid form of pharmaceutical such as a tablet or capsule containing plant extracts. The particles of compacted matter are subsequently screened to a uniform grain size, masked with titanium dioxide, talc, and highly dispersed silicon dioxide in a first mixing process, and treated with additional adjuvants in two more mixing steps.
The masked compacted matter has the flowability required for making tablets and is protected against moisture absorption. The extract portion is a minimum of 65 percent by weight, which allows for producing relatively small tablets that have low disintegration times due to masking.
Abstract: A pharmaceutical formulation in the form of a fast dissolving tablet comprising an active ingredient, sodium glycine carbonate and an acid capable of reacting rapidly with sodium glycine carbonate to release carbon dioxide.
Type:
Grant
Filed:
August 20, 2001
Date of Patent:
December 23, 2003
Assignee:
Chiesi Farmaceutici S.p.A.
Inventors:
Paolo Chiesi, Paolo Ventura, Rosa Mezzadri, Gaetano Brambilla, Daniela Acerbi
Abstract: Compositions and methods for systemically minimizing the inflammatory effects of TNF-&agr; are disclosed. The compositions include particles of bioactive glass with a particle size less than about 20 &mgr;m, alone or in combination with anti-inflammatory agents and other therapeutic agents. The compositions can include an appropriate carrier for oral, intramuscular, intraperitoneal or intravenous administration. When administered to a patient, the particles bring about elevated levels of IL-6 and do not cause elevated levels of TNF-&agr;.
Type:
Grant
Filed:
April 28, 2000
Date of Patent:
December 16, 2003
Assignee:
USBIOMATERIALS Corp.
Inventors:
David C. Greenspan, Sean Lee, Marlo tan Walpole
Abstract: The present invention provides storage stable, shaped particles of allotropic organic compounds. The particles of the present invention can be shaped according to the desired application. Preferred shapes of such particles are microspheres, particularly those having diameters of about 1 to about 1,000 microns. The stable shaped particles of the present invention are particularly well-suited to the fabrication of pharmaceutical formulations, particularly where sustained release and uniform bioavailability are desired. The storage stable particles are formed by a solid state crystallization of allotropic organic compounds. The solid state crystallization process of the present invention affords a means for achieving a storage stable crystalline form of said allotropic compound without loss or deterioration of the original particle dimensions.
Type:
Grant
Filed:
May 29, 2002
Date of Patent:
December 16, 2003
Inventors:
John-Claude Savoir, Juan Angeles, Aurelio De Gyves, Abraham Gomez
Abstract: A stable injectable composition includes a non-aqueous parasitic agent in a therapeutically effect amount, chosen from the group of avermectin, ivermectin, doramectin, abamectin, milbemycin and moxidecting, and an antigen in combination with a liquid carrier that also acts as an adjuvant for use with warm blooded animals and a method for treating parasitic diseases and preventing bacterial and viral diseases in warm blooded animals.
Abstract: The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions.
Type:
Grant
Filed:
March 20, 2000
Date of Patent:
December 9, 2003
Assignee:
Biosphere Medical, Inc.
Inventors:
Jean-Marie Vogel, Richard Thomas, Egisto Boschetti